Quick Facts: What Галидор Treats

• Peripheral Vascular Issues: Management of conditions characterized by restricted blood flow in the extremities, such as chronic lower limb ischemia.
• Cerebral Vascular Issues: Used in the management of chronic cerebral circulation disorders, including certain forms of discirculatory encephalopathy.
• Symptomatic Relief: Offers therapeutic benefits in alleviating symptoms like intermittent claudication (painful cramping during exercise) and certain types of vascular headaches.

---

Therapeutic Overview: Main Uses of Галидор

Галидор (Bencyclane) is primarily used for its actions that affect blood vessel function and muscle spasms. The medication is indicated for the management of certain peripheral circulation disorders. This includes conditions such as chronic lower limb ischemia and other forms of peripheral arterial occlusive disease, where it helps improve blood flow to the affected extremities, offering relief from symptoms like intermittent claudication and pain. Its actions are attributed to its properties as a spasmolytic agent, which works to relax the smooth muscles in the vascular walls.

In addition to its uses in the limbs, the drug is also utilized in the management of certain cerebral circulation disorders, including some presentations of discirculatory encephalopathy. Furthermore, the therapeutic profile extends to the symptomatic management of vascular headaches, such as migraines, in some clinical settings. These applications relate to the drug's ability to facilitate vasodilation and reduce muscle spasm, contributing to enhanced oxygen and nutrient supply to the tissues.

Eligibility Profile: Who Can and Cannot Use Галидор?

Official regulatory information defines specific populations for whom the use of Галидор (bencyclane) is either contraindicated or not recommended.

---

Populations for Whom Use is Contraindicated

The medicine must not be used in individuals with the following documented conditions or states:

Contraindication Domain	Specific Exclusions
Hypersensitivity	Known allergy to the active substance or any excipients.
Cardiovascular	Acute myocardial infarction; decompensated heart failure; severe cardiac arrhythmias or conduction disturbances (e.g., severe AV block).
Organ Dysfunction	Severe respiratory failure; severe renal (kidney) or hepatic (liver) failure.
Neurological	History of epilepsy or other forms of spasmophilia; recent cerebral event (e.g., hemorrhagic stroke, head injury) within the last 12 months.
Life Stage	Pregnancy; breastfeeding.

---

Restricted and Non-Recommended Use

Use is not recommended in the pediatric population, as safety and efficacy have not been established in children. The general adult population not meeting any of the above absolute contraindications is considered eligible for use, subject to a healthcare provider’s assessment.

Interactions with other medicines and products

The officially documented interaction profile for Galidor (Bencyclane fumarate) is characterized by mandatory restrictions and warnings for pharmacodynamic risks, as defined by regulatory authorities.

Pharmacodynamic Interactions

Co-administration with several classes of agents may lead to additive effects or an increased risk of cardiac complications. The effects of Anesthetics and Sedatives may be enhanced. The use of Sympathomimetics is associated with an increased risk of atrial and ventricular tachyarrhythmias.

Caution is required when combining Galidor with Cardio-depressive agents (such as beta-adrenergic blockers or Quinidine) and Cardiac Glycosides.

Interaction-Related Restrictions

Interaction Type	Interacting Agent	Official Regulatory Statement
Strict Prohibition	Alcohol (Ethanol)	Consumption of alcohol is strictly prohibited during treatment.
Dose Limitation	Hypokalemia-inducing agents (e.g., Diuretics, Steroid Hormones), Cardiac Glycosides, Cardio-depressive agents	Maximum daily dose must not exceed 150–200 mg when co-administered.

These restrictions address the potential for combined effects on cardiac function and the central nervous system. No interactions involving Cytochrome P450 (CYP) enzymes or drug transporters are explicitly documented in the official regulatory information.

Modulation of Vascular and Visceral Smooth Muscle Tone

The action of Bencyclane fumarate involves the non-competitive blockade of voltage-gated calcium channels ( CaV), located predominantly on the membranes of vascular and visceral smooth muscle cells. Inhibiting the influx of extracellular calcium ions ( Ca^2+) into the cell directly interrupts the excitation-contraction pathway, which is essential for muscle fiber shortening. This cellular event produces the fundamental physiological consequences of vasodilation (vessel widening) and smooth muscle relaxation (spasmolysis) in both vascular walls and involuntary visceral tissues.

Hemodynamic and Anti-Aggregatory Modulation

A secondary mechanistic domain involves the drug's influence on cell membrane stability and hemorheological characteristics. This is facilitated through a modest sodium channel blockade ( NaV) and a distinct anti-aggregatory effect that modulates the molecular steps required for blood platelets to adhere and clump. This dual mechanism—relaxing smooth muscle and adjusting the flow properties of the blood—modulates the overall peripheral resistance and contributes to the adjustment of peripheral tissue perfusion.

Administration Map: Official Use of Галидор (Bencyclane Fumarate)

The administration of Bencyclane fumarate is officially structured around two distinct regulatory routes: oral via the tablet form for long-term maintenance and intravenous (IV) injection for short-term or acute management.

---

Oral Maintenance Regimen

Oral use involves the tablet form and is intended for chronic circulatory support. Standard adult dosing typically falls within the range of 100 mg to 200 mg per single dose. The established dosing schedule is a divided regimen, commonly administered two to three times daily to maintain consistent therapeutic levels. A key administration condition is that the tablets should be taken with or immediately after meals to optimize drug exposure and ensure proper intake conditions.

---

Intravenous (IV) Acute Use

The solution for injection is reserved for use in supervised settings, such as hospitals, to manage acute vascular episodes. Acute dosing involves the administration of 50 mg or 100 mg per single infusion. The procedural requirements for the solution mandate that it must be diluted prior to infusion and delivered slowly over a measured duration, such as five minutes, for single-dose administration. The IV route is specifically intended for short-term courses rather than chronic therapy.

---

Population-Specific Guidelines

Official guidelines require that dosage adjustment is necessary for adult patients who present with hepatic or renal impairment due to the drug’s metabolism and excretion profile. Additionally, caution and potential dose modification are standard procedural steps advised for older adults.

Research evidence / Overview of Studies for Галидор (Bencyclane Fumarate)

---

Evidence for Use in Peripheral Arterial Occlusive Disease (PAOD)

Research exploring Bencyclane fumarate centered on its evaluation for peripheral arterial occlusive disease, a condition marked by functional limitations and insufficient blood flow in the limbs. Studies have primarily been conducted as randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time and involved comparing the medicine against a placebo (an inactive substance) over defined time intervals. The study populations were typically adults diagnosed with intermittent claudication, a condition where symptoms may vary in intensity. Researchers examined outcomes related to physical discomfort and changes in activity level, such as the distances patients could walk pain-free and the maximum distances walked.

Studies monitored how symptoms evolved in the observed populations. Some evidence, often categorized with data on the class of peripheral vasodilators, describes that trials monitored measurements of walking distance (PFWD and MWD) during the study period, which were then compared to the placebo group. Data show patterns related to patient-reported outcomes describing perceived discomfort and changes in activity level evaluated by the researchers.

Evidence for Use in Chronic Cerebral Circulation Disorders

Research has also explored Bencyclane fumarate in controlled, randomized studies focusing on chronic cerebral circulation disorders, conditions marked by functional limitations and cycles of stability and flare-ups, particularly in older adults. Studies explored how the drug was associated with outcomes related to systemic or functional imbalance. Researchers monitored changes using standardized doctor’s and study nurse’s symptom rating scales, alongside objective performance tests designed to assess psychomotor function.

Studies monitored how symptoms evolved in the observed populations, and research describes measurements of change recorded during the study period for certain symptom and performance ratings. Conversely, other double-blind studies for conditions associated with acute or disruptive episodes, such as ischemic cerebral infarction, reported no marked difference in outcomes between the treatment and control groups already receiving standard care.

What is Still Uncertain About the Research for Галидор

The evidence highlights what is known—and what is still uncertain—about this medicine. A primary limitation is the age and size of some of the pivotal studies, as sample sizes were modest. Evidence quality varies across studies, and comparative evidence against the newer, currently preferred standard-of-care treatments for peripheral vascular disease is lacking in recent meta-analyses. Long-term outcomes are not fully established, as follow-up durations were often limited to 12 months.

Key Studies & References

1. The long-term tolerability of bencyclane ('Fludilat') in patients with peripheral occlusive disease: a 48-week prospective double-blind controlled study versus placebo
2. [Patogenetic therapy of patients with diabetes mellitus type 2 and cerebral vascular insufficiency]

Common questions about Галидор (FAQ)

---

Q: Does Galidor affect blood pressure?

Studies and official information indicate that the active compound, Bencyclane fumarate, is associated with a slight decrease in systolic blood pressure. This observed effect is generally considered clinically insignificant, meaning it is not the primary purpose of the medication.

Q: Have any long-term studies been conducted on Galidor?

Long-term safety and tolerability have been examined in controlled clinical trials. These studies were used to assess the medicine for periods lasting up to 48 weeks (12 months) in populations with peripheral vascular conditions.

Q: What are the general signs that Galidor may not be suitable for the body?

The official safety profile notes the potential for serious and uncommon adverse reactions, such as atrial and ventricular tachyarrhythmia (a type of irregular heartbeat). If any unexpected or severe reactions occur, patients are instructed in official documents to seek professional medical advice immediately.

Q: What risks are associated with taking Galidor for the elderly?

Official guidelines advise that caution is necessary when prescribing this medicine to older adults. This caution is typically related to the need for potential dosage adjustment, as well as considering general risks associated with the drug's safety profile.

Q: Can Galidor improve memory or cognitive function?

Research has explored the drug's possible association with functional changes in chronic cerebral circulation disorders. This research monitored changes using objective tests designed to assess psychomotor function.

Q: Does Galidor affect the results of biochemical blood tests?

Official documents state that if treatment is prolonged, systematic laboratory testing of the blood is a requirement of the official safety documentation. This testing focuses on measuring blood rheological properties, which is the study of how blood flows.

Q: What official warnings exist regarding driving while taking Galidor?

The safety profile lists side effects that occur in the nervous system, such as dizziness, headache, and sleep disturbances. These effects may be associated with changes that could impair the ability to safely drive vehicles or operate complex machinery.

Q: How long does it usually take to feel the effect of Galidor?

Symptomatic relief may typically be felt within a few hours of administration. However, achieving optimal therapeutic results generally requires consistent use over several days or weeks.

Q: Does Galidor have a cumulative effect in the body?

The compound is often prescribed or administered using a divided dose regimen to maintain consistent therapeutic levels in the bloodstream. This schedule is designed based on the drug's pharmacokinetic profile.

Q: What is the typical duration of a course of treatment with Galidor, according to official information?

According to regional product information, the duration of treatment is determined by the prescribing doctor. For vascular conditions, courses typically last between two and three months, and for internal organ spasms, treatment generally does not exceed one to two months.

Q: What should a patient do if they forget to take one dose of Galidor?

Official product information describes that a forgotten dose should be administered as soon as it is remembered. However, if it is already time for the next scheduled dose, the official guidelines advise skipping the forgotten dose entirely and not taking a double dose.

How to Store and Dispose of Halidor (Bencyclane fumarate)

Storage and disposal requirements for Halidor are defined by official regulatory labeling to ensure product stability and safety. The medicine must be stored at a controlled room temperature, specifically between 15 C and 25 C (59 F to 77 F), and must not be stored above this range.

The product requires protection from environmental factors, mandating storage in a dry location and shielded from light. It must be kept in its original packaging. The labeled shelf life for the tablets is 5 years, and the medicine must not be used after the expiration date. Crucially, the product must always be stored out of the sight and reach of children. Disposal of unused or expired Halidor must strictly adhere to local regulatory and pharmaceutical waste requirements.